WO2025006848A1 - Ingénierie de surface cellulaire d'une distribution de gène thérapeutique personnalisée - Google Patents

Ingénierie de surface cellulaire d'une distribution de gène thérapeutique personnalisée Download PDF

Info

Publication number
WO2025006848A1
WO2025006848A1 PCT/US2024/035972 US2024035972W WO2025006848A1 WO 2025006848 A1 WO2025006848 A1 WO 2025006848A1 US 2024035972 W US2024035972 W US 2024035972W WO 2025006848 A1 WO2025006848 A1 WO 2025006848A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
cells
fluorescein
nucleic acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/035972
Other languages
English (en)
Inventor
Leyuan MA
Letitia CHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
University of Pennsylvania Penn
Original Assignee
Childrens Hospital of Philadelphia CHOP
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP, University of Pennsylvania Penn filed Critical Childrens Hospital of Philadelphia CHOP
Priority to EP24832987.2A priority Critical patent/EP4735583A1/fr
Publication of WO2025006848A1 publication Critical patent/WO2025006848A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present disclosure relates generally to the fields of molecular biology. More particularly, the disclosure relates to improved methods of transduction, such as for therapeutic gene delivery.
  • the fluorescein may be5-carboxyfluorescein (5-FAM), FITC, or 6- carboxyfluorescein (6’FAM).
  • the fluorescein may be NHS-5’FAM, Maleimide-5’FAM, or 1,2-Distearoyl-sn- glycero-3-phosphoethanolamine (DSPE)-Poly-ethylene-glycol(PEG)-Fluorescein.
  • the cell with low, undetectable or essentially no expression of hLDLR may a human naive T cell, resting human T cells, a human B cell, human epithelial cell, murine immune cell, or canine immune cell, monkey immune cell, or cancer cell line (e.g., SUP-B15 or Raji).
  • the murine immune cell, monkey immune cell, or canine immune cell may be a T cell, NK cell, or a hematopoietic cell.
  • the 5-FAM may conjugated to N-hydroxysuccinimide at the 5’ carbon (NHS-5’-FAM) or may be is conjugated to an antibody targeting a cell surface protein, such as wherein the cell surface protein is CD71 on K562 cells, CD3, CD4, CD8, CD5, or CD7 on T cells, or CD 19, CD20, or CD22 on B cells.
  • the cell may be have been transduced with a pseudotyped lentivirus, such as a scFv-truncated vesicular stomatitis virus envelope glycoprotein (VSV-G) pseudotyped lentivirus, e.g., wherein the VSV-G pseudotyped lentivirus comprises a VSV-G hinge, intracellular domain and transmembrane domain fused to an antifluorescein scFv.
  • the anti-fluorescein scFv may be positioned at the N terminal of the lentivirus.
  • the anti-fluorescein scFv may comprise 2A9M derived from fluorescein targeting antibody FITC-E2.
  • the anti-fluorescein scFv is positioned at the N terminus of the chimeric protein. In some aspects, the anti-fluorescein scFv is a 2A9M scFv derived from fluorescein targeting antibody FITC-E2. In certain aspects, the anti-fluorescein is fused to a VSV-G hinge, transmembrane and intracellular domain. In some aspects, the fusion protein is under control of a constitutive promoter. In certain aspects, the constitutive promoter is CMV, CAG, or EFla.
  • Another embodiment provides a vector comprising the nucleic acid of the present embodiments or aspects thereof (e.g., a cell conjugated to 5 -carboxyfluorescein (5-FAM), wherein the cell has low or essentially no expression of human low density lipoprotein receptor (hLDLR)).
  • the vector is a HIV-1 -derived lentiviral vector.
  • a host cell comprising the nucleic acid of the present embodiments or aspects thereof (e.g., a nucleic acid encoding a VSV-G chimeric protein linked to an anti-fluorescein antibody or fragment thereof).
  • a further embodiment provides a polypeptide encoded by the nucleic acid of any one of the present embodiments or aspects thereof (e.g., a nucleic acid encoding a VSV-G chimeric protein linked to an anti-fluorescein antibody or fragment thereof).
  • Another embodiment provides a pseudotyped lentiviral vector particle comprising a VSV-G envelope and the polypeptide comprising a VSV-G chimeric protein linked to an anti- fluorescein antibody or fragment thereof.
  • Another embodiment provides use of naive, resting or activated human T cells pre-labeled with fluorescein followed by addition of VSVG/aFITC dual envelope pseudotyped lentivirus using routine transduction method (e.g., spin transduction) for gene therapy.
  • routine transduction method e.g., spin transduction
  • FIG. 1 Schematics comparing lentiviral transduction of the standard low hLDLR expressing cells with transduction of chemically labelled cells by scFv pseudotyped lentiviruses.
  • FIG. 2 Schematic showing genetic engineering of scFv-truncVSVG, used in pseudotyping of lentiviral particles.
  • the N terminus consists of the 2A9M scFv, derived from fluoresecein targeting antibody FITCE2, followed by the hinge, transmembrane, and intracellular domains of VSVG respectively.
  • FIG. 3A WT K562 cells unlabeled and transduced with WT virus
  • FIG. 3B hLDLR KO K562 cells unlabeled and transduced with WT virus
  • FIG. 3C hLDLR KO K562 cells transduced with scFv-truncVSV-G pseudotyped virus
  • FIG. 3D labelled hLDLR KO K562 cells transduced with scFv-truncated VSV-G pseudotyped virus.
  • FIG. 4 High speed concentration of scFv-truncVSVG pseudotyped lentivirus supernatant results in increased transduction efficiency. Methodology identical to FIG 2., but 38 mL of virus supernatant was concentrated via high-speed centrifuge 15,600 rpm for 20 hrs at 4°C and concentrated to 2 mL. Dilutions of concentrated virus were generated by diluting concentrated virus with medium.
  • FIG. 5 Sequences of fusion protein.
  • FIG. 6 Project Overview - cell surface engineering and viral pseudotyping.
  • FIG. 7 WT and KO LDL-R K562 cells were transduced with VSV-G lentivirus with or without 20 pg/ml of polybrene. BFP expression was measured 48 hours post transduction using flow cytometry.
  • FIG. 8 WT K562 cells were incubated with 10 pg/ml II antibody with or without 20 pg/ml polybrene for 30 minutes on ice and BFP expression was measured using flow cytometry 48 hours post transduction.
  • FIG. 9 KO LDL-R K562 cells were incubated with various linker lengths indicated in the figure for 40 minutes at 37°C and BFP expression was measured using flow cytometry 48 hours post transduction.
  • FIG. 10 KO LDL-R K562 cells were incubated with increasing concentrations of Maleimide-FITC, indicated in the figure, for 40 minutes at 37°C and BFP level was measured using flow cytometry 48 hours post transduction.
  • FIG. 11 KO LDL-R K562 cells were incubated with either 1 pM NHS-FITC or 500nM Amph-FITC 5k or 5 pM Maleimide-FITC or unlabeled for 40 minutes at 37°C and BFP level was measured using flow cytometry 48 hours post transduction.
  • FIG. 12 Cell proliferation of NHS-FITC and Amph-FITC labeled cells with and without polybrene (20 pg/ml) and unlabeled cells with or without polybrene was calculated using a hemocytometer and trypan blue.
  • FIG. 13 KO LDL-R labeled and unlabeled K562 cells were incubated with 100 pM MethyLBeta-Cyclodextrin clathrin inhibitor for Cup at 37°C, followed by transduction with aFITC/VSV-G lentivirus. BFP level was measured using flow cytometry, 48 hours post transduction.
  • FIG. 14 Virus binding is a better indicator of VSV-G LV gene delivery efficiency than LDLR expression.
  • WT or hLDLR K562 cells were stained with virus for 30min at room temperature, then stained with II antibody for 30min on ice, followed by anti-mouse IgG antibody for 20min on ice, then analyzed by flow cytometry. The same procedure was performed for all other mammalian cell lines indicated in the plots. The The coefficient of determination (R 2 ) was calculated in Prism.
  • FIG. 15 Surface modification improves VSV-G LV transduction of various cell lines and primary cells. Mammalian cell lines as indicated in the plot and pre-activated canine T cells were labeled with NHS-FITC (1 pM) for 40 minutes at 37°C, followed by virus transduction. BFP level was measured using flow cytometry 48 hours post-transduction.
  • FIG. 16 Naive human T cell transduction and T cell phenotypes. Unactivated T cells (Donor 1) were pre-labeled with both FITC-conjugated anti-CD5 and anti-CD45 antibody followed by virus transduction in the presence of polybrene (lOug/ml).
  • FIG. 17 Donor 2 - Optimization of the labeling approach for naive human T cell transduction.
  • Unactivated T cells (Donor 2) were pre-labeled with NHC-FITC, FITC- conjugated anti-CD5, anti-CD45 antibody, anti-CD5/CD45 combo or anti-CD19, followed by virus transduction in the presence or absence of polybrene (lOug/ml).
  • Cells were maintained in the presence of hIL2 (lOng/ml) and analyzed by flow cytometry 7 days post- transduction for CD19 CAR expression (APC channel).
  • UNL unlabeled
  • NTD untransduced.
  • FIG. 18 Donor 2 - Naive human T cell transduction phenotyping. Transduced T cells from Fig.17 were stained with CD45RA-Alex488 and CCR7-PE to assess the changes of T cell phenotypes after transduction. Activated T cells were included as control. Naive T cell phenotype: CD45RA+CCR7+. CD45RA+CCR7+ naive T cells were further analyzed for the CD 19 CAR expression (APC channel).
  • the present studies aimed to overcome this limitation in these cell types with the design of a broad method to increase the efficiency of transduction.
  • the studies here showed that in cells without hLDLR expression, chemical labelling resulted in increased lentiviral transduction ex vivo, using pseudotyped lentivirus.
  • pseudotyped lentivirus there is provided herein a strategy to chemically label cell surfaces with a small molecule, priming them for docking and lentivirus entry. These cells can then be efficiently transduced by pseudotyped lentiviruses that contain envelope proteins that target the cell-surface small molecule. This strategy dramatically improved lentiviral transduction efficiency (FIG. 1).
  • the present methods provide a strategy of chemically labeling cells, by various methods, to offer a simple platform to achieve higher efficiency lentiviral transduction with high applicability and flexibility towards cell type.
  • Chemical labelling makes use of easily purchased chemicals and does not alter cell genotype.
  • Lentiviral pseudotyping overcomes the limitation of hLDLR entirely, providing methods for lentiviral-based transduction in animal cells such as murine and canine cells, as well as non-transducible human cell types such as naive T cells.
  • the low-density lipoprotein receptor is a mosaic protein of 839 amino acids (after removal of 21 -amino acid signal peptide) that mediates the endocytosis of cholesterol- rich low-density lipoprotein (LDL). It is a cell-surface receptor that recognizes apolipoprotein Bl 00 (ApoBlOO), which is embedded in the outer phospholipid layer of very low-density lipoprotein (VLDL), their remnants - i.e. intermediate-density lipoprotein (IDL), and LDL particles. The receptor also recognizes apolipoprotein E (ApoE) which is found in chylomicron remnants and IDL. In humans, the LDL receptor protein is encoded by the LDLR gene on chromosome 19. It belongs to the low-density lipoprotein receptor gene family. It is most significantly expressed in bronchial epithelial cells and adrenal gland and cortex tissue.
  • the human LDLR gene resides on chromosome 19 at the band 19pl3.2 and is split into 18 exons.
  • Exon 1 contains a signal sequence that localizes the receptor to the endoplasmic reticulum for transport to the cell surface.
  • exons 2-6 code the ligand binding region; 7-14 code the epidermal growth factor (EGF) domain; 15 codes the oligosaccharide rich region; 16 (and some of 17) code the membrane spanning region; and 18 (with the rest of 17) code the cytosolic domain.
  • EGF epidermal growth factor
  • the N-terminal domain of the LDL receptor which is responsible for ligand binding, is composed of seven sequence repeats (-50% identical).
  • Each repeat referred to as a class A repeat or LDL- A, contains roughly 40 amino acids, including 6 cysteine residues that form disulfide bonds within the repeat.
  • each repeat has highly conserved acidic residues which it uses to coordinate a single calcium ion in an octahedral lattice. Both the disulfide bonds and calcium coordination are necessary for the structural integrity of the domain during the receptor's repeated trips to the highly acidic interior of the endosome.
  • EGF precursor homology domain (EGFP domain). This shows approximately 30% homology with the EGF precursor gene.
  • growth factor repeats A, B and C. A and B are closely linked while C is separated by the YWTD repeat region, which adopts a beta-propeller conformation (LDL-R class B domain). It is thought that this region is responsible for the pH-dependent conformational shift that causes bound LDL to be released in the endosome.
  • a third domain of the protein is rich in O-linked oligosaccharides but appears to show little function. Knockout experiments have confirmed that no significant loss of activity occurs without this domain. It has been speculated that the domain may have ancestrally acted as a spacer to push the receptor beyond the extracellular matrix.
  • the single transmembrane domain of 22 (mostly) non-polar residues crosses the plasma membrane in a single alpha helix.
  • the cytosolic C-terminal domain contains ⁇ 50 amino acids, including a signal sequence important for localizing the receptors to clathrin-coated pits and for triggering receptor- mediated endocytosis after binding. Portions of the cytosolic sequence have been found in other lipoprotein receptors, as well as in more distant receptor relatives.
  • the non-transducible cells may be labeled with fluorescein or its derivatives, such as by a small molecule including but not limited to NHS-5’FAM, Maleimide-5’FAM, 1,2- Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)-Poly-ethylene-glycol(PEG)-
  • fluorescein or its derivatives such as by a small molecule including but not limited to NHS-5’FAM, Maleimide-5’FAM, 1,2- Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)-Poly-ethylene-glycol(PEG)-
  • Fluorescein or by a bridge molecule, such as an FITC -conjugated antibody specific for a target cell surface protein.
  • FITC Fluorescein
  • 5 ’FAM Fluorescein
  • 6’ FAM Fluorescein
  • the chemical group can also have a sulfo-modification which introduces a negative charge and limits the chemical labeling on cell surface proteins.
  • the above molecules label cells through different labeling chemistries, for example, the NHS group reacts with the primary amine groups on protein molecules, the maleimide group reacts with free thiol groups on proteins, and DSPE directly insert in the lipid bilayer of cell membrane.
  • Cells can be labeled with a single fluorescein-bearing molecule, or a combination of different fluorescein-bearing molecules.
  • VSV-G chimeric proteins comprising a N-terminal singlechain antibody fragments (scFv) directed against fluorescein, wherein the VSV-G and the scFv may be separated by linker, such as a flexible linker.
  • linker such as a flexible linker.
  • nucleic acid encoding the VSV-G chimeric protein and vector comprising the nucleic acid molecule of VSV-G chimeric fusion protein.
  • nucleic acid encoding the vector pCAG-FITC E2-VSV is provided below.
  • the present nucleic acid may have at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 1:
  • SEQ ID NO:1 (pCAG-FITC E2-VSV) 1 gtcgacattg attattgact agttattaat agtaatcaat tacggggtca ttagttcata
  • nucleic acid encoding the fusion protein is provided below.
  • the present nucleic acids may have at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NOs:2-7.
  • Myc tag GAAGCTGATCAGCGAGGAGGATCTG (SEQ ID N0:4)
  • VSVG-hinge aaaaatccaatcgagcttgtagaaggttggttcagtagttggaaaagctctattgcctct (SEQ ID NO: 5)
  • VSVG-TM tttttctttatcatagggttaatcattggactattcttggttctc (SEQ ID NO: 7)
  • the present polypeptides may have at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NOs:8-14.
  • Myc tag EQKLISEEDL (SEQ ID NO: 10)
  • VSVG-TM FFFIIGLIIGLFLVL (SEQ ID NO: 13)
  • RVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 14)
  • Nucleic acid molecules which are also referred to herein as polynucleotides or nucleic acid sequences, include DNA, such as cDNA or genomic DNA, and RNA. It is understood that the term “RNA” as used herein comprises all forms of RNA including mRNA, tRNA and rRNA but also genomic RNA, such as in case of RNA of RNA viruses. In particular, embodiments reciting “RNA” are directed to mRNA. Further included are nucleic acid mimicking molecules known in the art such as synthetic or semi-synthetic derivatives of DNA or RNA and mixed polymers, both sense and antisense strands. They may contain additional non-natural or derivatized nucleotide bases, as will be readily appreciated by those skilled in the art.
  • nucleic acid mimicking molecules or nucleic acid derivatives include peptide nucleic acid (PNA), phosphorothioate nucleic acid, phosphoramidate nucleic acid, 2'-O-methoxyethyl ribonucleic acid, morpholino nucleic acid, hexitol nucleic acid (HNA) and locked nucleic acid (LNA), an RNA derivative in which the ribose ring is constrained by a methylene linkage between the 2'-oxygen and the 4'-carbon (see, for example, Braasch and Corey, Chemistry & Biology 8, 1-7 (2001)).
  • PNA peptide nucleic acid
  • HNA hexitol nucleic acid
  • LNA locked nucleic acid
  • PNA is a synthetic DNA-mimic with an amide backbone in place of the sugar-phosphate backbone of DNA or RNA, as described by Nielsen et al., Science 254:1497 (1991); and Egbolm et al., Nature 365:666 (1993).
  • polypeptide as used herein relates to polypeptides as well as peptides.
  • polypeptide as used herein interchangeably with the term “protein”, describes linear molecular chains of amino acids, including single chain proteins or their fragments, containing more than 30 amino acids, whereas the term “peptide” as used herein describes a group of molecules consisting of up to 30 amino acids.
  • (Poly)peptides may further form oligomers consisting of at least two identical or different molecules. The corresponding higher order structures of such multimers are, correspondingly, termed homo- or heterodimers, homo- or heterotrimers etc. Such multimers also fall under the definition of the term “(poly)peptide”.
  • polypeptide and peptide also refer to naturally modified polypeptides/peptides where the modification results from, e.g., glycosylation, acetylation, phosphorylation and similar modifications which are well known in the art.
  • the present vector is a plasmid, cosmid, virus, bacteriophage or another vector used, e.g., conventionally in genetic engineering.
  • the nucleic acid molecules provided herein may be inserted into several commercially available vectors suitable for the expression of eukaryotic proteins.
  • Non-limiting examples include prokaryotic plasmid vectors, such as the pUC-series, pBluescript (Stratagene), the pET-series of expression vectors (Novagen) or pCRTOPO (Invitrogen) and vectors compatible with an expression in mammalian cells like pREP (Invitrogen), pcDNA3 (Invitrogen), pCEP4 (Invitrogen), pMClneo (Stratagene), pXTl (Stratagene), pSG5 (Stratagene), EBO-pSV2neo, pBPV-1, pdBPVMMTneo, pRSVgpt, pRSVneo, pSV2-dhfr, pIZD35, pLXIN, pSIR (Clontech), pIRES-EGFP (Clontech), pEAK-10 (Edge Biosystems) pTriEx-Hygro (Novage
  • the present nucleic acid molecules may also be inserted into vectors such that a translational fusion with another polynucleotide is generated.
  • the other polynucleotide may encode a protein which may, e.g., increase the solubility and/or facilitate the purification of the chimeric protein.
  • Non-limiting examples include pET32, pET41, pET43.
  • vector modification techniques see Sambrook and Russell “Molecular Cloning, A Laboratory Manual”, Cold Spring Harbor Laboratory, N.Y. (2001).
  • vectors can contain one or more origins of replication (ori) and inheritance systems for cloning or expression, one or more markers for selection in the host, e. g., antibiotic resistance, and one or more expression cassettes.
  • Suitable origins of replication (ori) include, for example, the Col El, the SV40 viral and the M 13 origins of replication.
  • the coding sequences inserted in the vector can e.g. be synthesized by standard methods, or isolated from natural sources. Ligation of the coding sequences to transcriptional regulatory elements and/or to other amino acid encoding sequences can be carried out using established methods. Transcriptional regulatory elements (parts of an expression cassette) ensuring expression of the coding sequences are well known to those skilled in the art. These elements comprise regulatory sequences ensuring the initiation of the transcription (e. g., translation initiation codon, promoters, enhancers, and/or insulators), internal ribosomal entry sites (IRES) (Owens, Proc. Natl. Acad. Sci.
  • Additional regulatory elements may include transcriptional as well as translational enhancers, and/or naturally associated or heterologous promoter regions.
  • the nucleic acid molecule of the present disclosure is operatively linked to such expression control sequences allowing its expression.
  • the vector may further comprise nucleotide sequences encoding secretion signals as further regulatory elements. Such sequences are well known to persons skilled in the art.
  • leader sequences capable of directing the expressed polypeptide to a cellular compartment may be added to the coding sequence of the polynucleotide of the present disclosure. Such leader sequences are well known in the art.
  • regulatory elements ensuring the initiation of transcription comprise the cytomegalovirus (CMV) promoter, SV40-promoter, RSV-promoter (Rous sarcome virus), the lacZ promoter, the gailO promoter, human elongation factor la-promoter, CMV enhancer, CaM-kinase promoter, the Aulographa califomica multiple nuclear polyhedrosis virus (AcMNPV) polyhedral promoter or the S V40-enhancer.
  • CMV cytomegalovirus
  • SV40-promoter RSV-promoter
  • RSV-promoter Rousarcome virus
  • the lacZ promoter the lacZ promoter
  • the gailO promoter human elongation factor la-promoter
  • CMV enhancer CMV enhancer
  • CaM-kinase promoter the Aulographa califomica multiple nuclear polyhedrosis virus (AcMNPV) polyhedral promoter
  • Examples for further regulatory elements in prokaryotes and eukaryotic cells comprise transcription termination signals, such as SV40- poly-A site or the tk-poly-A site or the SV40, lacZ and AcMNPV polyhedral polyadenylation signals, downstream of the polynucleotide.
  • the present vectors may comprise a selectable marker. Examples of selectable markers include neomycin, ampicillin and hygromycin resistance and the like. Specifically designed vectors allow the shuttling of DNA between different hosts, such as bacteria-fungal cells or bacteria-animal cells.
  • An expression vector as used herein is capable of directing the replication, and the expression, of the nucleic acid molecule and encoded VSV-G chimeric protein.
  • Suitable expression vectors which comprise the described regulatory elements are known in the art such as pGreenPuro (System Biosciences, Mountain View, Calif., USA), pRc/CMV, pcDNAl , pcDNA3 (In-Vitrogene, as used, inter alia in the appended examples), pSPORTl (GIBCO BRL) or pGEMHE (Promega), or prokaryotic expression vectors, such as lambda gtl 1 , pJOE, the pBRl-MCS-series.
  • nucleic acid molecules of the present disclosure as described herein above may be designed for direct introduction or for introduction via liposomes, phage vectors or viral vectors (e.g., adenoviral, retroviral) into the cell. Additionally, baculo viral systems or systems based on Vaccinia Virus or Semliki Forest Virus can be used as eukaryotic expression system for the nucleic acid molecules of the present disclosure.
  • Suitable prokaryotic hosts comprise, e.g., bacteria of the species Escherichia, Streptomyces, Salmonella or Bacillus.
  • Suitable eukaryotic host cells are, e.g., yeasts such as Saccharomyces cerevisiae, Pichia pastoris, Schizosaccharomyces pombe or chicken cells, such as, e.g., DT40 cells.
  • Insect cells suitable for expression are, e.g., Drosophila S2, Drosophila Kc, or Spodoptera Sf9 and Sf21 cells.
  • Suitable zebrafish cell lines include, without being limiting, ZFL, SJD or ZF4.
  • Mammalian host cells that could be used include, human Hela, HEK293, HEK293T, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, COS 1 , COS 7 and CV1, quail QC1-3 cells, mouse L cells, mouse sarcoma cells, Bowes melanoma cells, human CAP or CAP-T cells and Chinese hamster ovary (CHO) cells. Also within the scope of the present present disclosure are primary mammalian cells or cell lines. Primary cells are cells which are directly obtained from an organism.
  • Suitable primary cells are, for example, mouse embryonic fibroblasts (MEF), mouse primary hepatocytes, cardiomyocytes and neuronal cells as well as mouse muscle stem cells (satellite cells), human dermal and pulmonary fibroblasts, human epithelial cells (nasal, tracheal, renal, placental, intestinal, bronchial epithelial cells), human secretory cells (from salivary, sebaceous and sweat glands), human endocrine cells (thyroid cells), human adipose cells, human smooth muscle cells, human skeletal muscle cells, and stable, immortalized cell lines derived thereof (for example hTERT or oncogene immortalized cells).
  • MEF mouse embryonic fibroblasts
  • mouse primary hepatocytes hepatocytes
  • cardiomyocytes and neuronal cells
  • neuronal cells as well as mouse muscle stem cells (satellite cells)
  • human dermal and pulmonary fibroblasts human epithelial cells (nasal,
  • the host cell in accordance with this embodiment may for example be employed in methods for the amplification of vectors of the present disclosure, for the production of the fusion protein of the present disclosure or for the direct production of lentivirus particles, as described in more detail herein below.
  • the present disclosure further relates to a polypeptide encoded by the nucleic acid molecule provided herein.
  • a method of producing the VSV-G chimeric protein comprising culturing the host cell under suitable conditions and isolating the produced VSV-G fusion protein.
  • Suitable conditions for culturing a prokaryotic or eukaryotic host are well known to the person skilled in the art.
  • suitable conditions for culturing bacteria are growing them under aeration in Luria Bertani (LB) medium.
  • the medium can be buffered or supplemented with suitable additives known to enhance or facilitate both.
  • E. coli can be cultured from 4 to about 37° C., the exact temperature or sequence of temperatures depends on the molecule to be over-expressed. In general, the skilled person is also aware that these conditions may have to be adapted to the needs of the host and the requirements of the protein expressed.
  • an inducible promoter controls the nucleic acid of the present disclosure in the vector present in the host cell
  • expression of the polypeptide can be induced by addition of an appropriate inducing agent. Suitable expression protocols and strategies are known to the skilled person.
  • mammalian cell culture can, e.g., be carried out in RPMI, Williams’ E or DMEM medium containing 10% (v/v) FCS, 2 mM L-glutamine and 100 U/ml penicillin/streptomycine.
  • the cells can be kept, e.g., at 37° C. or at 41° C. for DT40 chicken cells, in a 5% CO2, water saturated atmosphere.
  • Suitable media for insect cell culture is, e.g., TNM+10% FCS or SF900 medium.
  • Insect cells are usually grown at 27° C. as adhesion or suspension culture.
  • Suitable expression protocols for eukaryotic or vertebrate cells are well known to the skilled person and can be retrieved, e.g., from Sambrook and Russel, loc. cit.
  • isolated refers to a selective accumulation of the produced VSV-G chimeric protein, by removing the produced VSV-G chimeric protein from the host cells or from the medium in which the host cells have been cultured.
  • the isolated VSV-G chimeric protein is 100% pure, i.e., is free of any other components that are not the VSV-G chimeric protein of the present disclosure.
  • Methods of isolation of the chimeric protein produced are well-known in the art and comprise, without limitation, method steps such as ion exchange chromatography, gel filtration chromatography (size exclusion chromatography), affinity chromatography, high pressure liquid chromatography (HPLC), reversed phase HPLC, disc gel electrophoresis or immunoprecipitation, see, for example, in Sambrook and Russel, loc. cit.
  • the lentiviral vector particle may be pseudotyped with (a) a VSV-G chimeric protein domain encoded by the nucleic acid molecule of the present disclosure; and (b) a VSV-G not linked to a (poly)peptide comprising or consisting of a cell membrane-binding domain.
  • a “lentiviral vector particle”, also referred to herein as a “lentiviral vector”, is a vector based on a lentivirus virion, i.e., a subclass of retroviruses that can integrate into the genome of non-dividing target cells.
  • lentivirus virion i.e., a subclass of retroviruses that can integrate into the genome of non-dividing target cells.
  • a unique feature of lentiviruses is that they have a self-inactivated (SIN) region of replication in contrast to other retroviral vectors.
  • Lentiviruses are well known in the art and have been described in detail, e.g., in Retroviruses, Coffin J M, Hughes S H, Varmus H E, Cold Spring Harbor (N.Y.): Cold Spring Harbour Laboratory Press; 1997; ISBN- 10:0-87969-571-4; O'Connell R M, Balazs A B, Rao D S, Kivork C, Yang L, Baltimore D.
  • Lentiviral vector delivery of human interleukin-7 (hlL-7) to human immune system (HIS) mice expands T lymphocyte populations.
  • a lentiviral vector particle can be based, e.g., on a lentivirus of the group of bovine, equine, feline, ovine/caprine or primate lentiviruses.
  • the lentiviral vector is based on a primate lentivirus such as HIV1, HIV2 or SIV virus.
  • the lentiviral vector is based on an HIV 1 lentivirus.
  • most (commercially available) lentiviral vectors represent a mixture of viral constituents from different viruses and are, hence, to some extent “hybrid” vectors.
  • a lentiviral vector may comprise constituents from HIV1, VSVg, CMV, WPRE viruses. Such hybrid vectors are explicitly envisaged in accordance with the present disclosure.
  • proliferative refers to the modulation of the cell type specificity of a viral vector by integration of foreign viral envelope proteins.
  • This approach is well known in the art and has been described for example in Bischof et al. (Flexibility in cell targeting by pseudotyping lentiviral vectors. Methods Mol Biol. 2010; 614:53-68).
  • host tropism can be altered and/or the stability of the virus can be decreased or increased.
  • VSV-G for pseudotyping a lentiviral virus has been described, e.g., in Burns et al.
  • VSV-G not linked to a (poly)peptide comprising or consisting of a cell membrane-binding domain is also referred to herein as wild type VSV-G.
  • wild type only refers to the fact that no cell membrane-binding domain is fused to the VSV-G employed.
  • VSV-G the use of non-naturally occurring (i.e., modified) VSV-G molecules is not excluded, as long as they are not linked to a (poly)peptide comprising or consisting of a cell membrane-binding domain.
  • lentivirus vector particle that is pseudotyped with two different types of VSV-G proteins, namely with the present VSV-G chimeric protein and with a VSV-G that has not been fused to a cell membrane-binding domain, i.e., a wild-type (wt) VSV-G (option (b)).
  • wt wild-type
  • VSV-G cell membrane-binding domain
  • each individual lentivirus vector particle expresses both modified and wild type VSV-G glycoproteins on its surface.
  • the present disclosure further relates to a method of producing the pseudotyped lentiviral vector particle, the method comprising transfecting into a host cell (i) one or more packaging plasmids encoding the virion proteins and accessory proteins needed for efficient production and packaging of the LTR-containing nucleic acid; (ii) a vector comprising the nucleic acid molecule of the present disclosure; and (iii) a vector comprising a nucleic acid molecule encoding a VSV-G not linked to a (poly)peptide comprising or consisting of a cell membrane-binding domain.
  • pseudotyped lentiviral vectors are well known in the art and have been described, e.g., in Naldini, L. (1998).
  • Host cells in particular HEK 293, HEK293T, CAP or CAP-T cells are employed and a number of vectors, including the packaging vector(s) encoding the viral proteins, such as e.g. the capsid and the reverse transcriptase, as well as vectors carrying the nucleic acid molecules to be additionally introduced into the pseudotyped lentiviral vector particle are transfected or electroporated into these cells, or nucleofection is used to transfer said vectors.
  • further vectors containing the genetic material to be delivered by the pseudotyped lentiviral vector particle may be transfected.
  • vectors may be introduced into the host cells by direct introduction or by introduction via electroporation (using for example Multiporator (Eppendorf), Genepulser (BioRad), MaxCyte Transfection Systems (Maxcyte)), PEI (Polysciences Inc. Warrington, Eppelheim), Ca 2+ -mediated transfection or via liposomes (for example: “Lipofectamine” (Invitrogen)), non-liposomal compounds (for example: “Fugene” (Roche) or nucleofection (Lonza)) into cells.
  • Multiporator Eppendorf
  • Genepulser BioRad
  • MaxCyte Transfection Systems Maxcyte Transfection Systems
  • PEI Polysciences Inc. Warrington, Eppelheim
  • Ca 2+ -mediated transfection or via liposomes for example: “Lipofectamine” (Invitrogen)
  • non-liposomal compounds for example: “Fugene” (Roche) or nucleo
  • the present disclosure further relates to a method for transducing cells, the method comprising the step of contacting cells to be transduced with the pseudotyped lentiviral vector particle under conditions suitable for transduction, thereby transducing said cells.
  • transducing is well known in the art and refers to the process of introducing genetic material into a cell and, optionally, its subsequent integration into the genome of said cell via viral vector particles.
  • Said genetic material comprises or consists of viral RNA combined with one or more target RNA sequences (hereinafter referred to as target sequences) comprised in said viral vector particles intended for integration into the genome of a target cell.
  • contacting refers to bringing the cells to be transduced (also referred to herein as “target cells”) into contact with a retroviral vector so that the transduction event can occur.
  • targets cells also referred to herein as “target cells”
  • Conditions for contacting that allow the transduction event to occur are well known in the art and may depend to a certain extent on the cell to be transduced. For example, some target cells are more difficult to transfect than other cells and may need to be transitioned into a specific culture medium before transduction with a viral vector can be achieved.
  • Jacome et al. Lidiral-mediated Genetic Correction of Hematopoietic and Mesenchymal Progenitor Cells from Fanconi Anemia Patients.
  • the cells to be transduced can be any cells of interest that are to be targeted for transduction with a viral vector, particularly non-transducible cells, such as with low LDLR.
  • the term “cell/cells” as used herein can refer to single and/or isolated cells or to cells that are part of a multicellular entity such as a tissue, an organism or a cell culture. In other words the method can be performed in vivo, ex vivo or in vitro.
  • the cells to be transduced are eukaryotic cells including any cell of a multi-cellular eukaryotic organism, more specifically cells from animals like vertebrates. More particularly, the cells to be transduced are mammalian cell.
  • cells of different mammalian subclasses such as prototheria or theria may be used.
  • the subclass of theria in particular cells of animals of the infraclass eutheria, more particularly of the order primates, artiodactyla, perissodactyla, rodentia and lagomorpha are used in the method of the present disclosure.
  • a cell to be used in the method of the present disclosure based on the tissue type and/or capacity to differentiate equally depending on the goal to be achieved by modifying the genome via transducing a target cell according to the method of the present disclosure.
  • a germ cell is a cell that gives rise to gametes and thus is continuous through the generations.
  • Stem cells can divide and differentiate into diverse specialized cell types as well as self-renew to produce more stem cells. In mammals there are two main types of stem cells: embryonic stem cells and adult stem cells.
  • Somatic cells include all cells that are not gametes, gametocytes or undifferentiated stem cells.
  • the cells of a mammal can also be grouped by their ability to differentiate.
  • a totipotent (also known as omnipotent) cell is a cell that is able to differentiate into all cell types of an adult organism including placental tissue such as a zygote (fertilized oocyte) and subsequent blastomeres, whereas pluripotent cells, such as embryonic stem cells, cannot contribute to extraembryonic tissue such as the placenta, but have the potential to differentiate into any of the three germ layers endoderm, mesoderm and ectoderm.
  • Multipotent progenitor cells have the potential to give rise to cells from multiple, but limited number of cell lineages.
  • oligopotent cells that can develop into only a few cell types and unipotent cells (also sometimes termed a precursor cell) that can develop into only one cell type.
  • unipotent cells also sometimes termed a precursor cell
  • tissues muscle tissue, nervous tissue, connective tissue and epithelial tissue that cells to be used in the method of the present disclosure can be derived from, such as for example lymphoid lineage cells or neuronal stem cells.
  • lymphoid lineage cells refers to cells that are involved in the generation of lymphocytes and lymphocytes per se.
  • lymphocyte refers to small lymphocytes (B and T lymphocytes, plasma cells) and natural killer cells as well-known in the art. Lymphoid lineage cells further include, e.g., lymphoid dendritic cells, as well as lymphocyte progenitor cells such as pro-lymphocytes, lymphoblasts, common lymphoid progenitor cells.
  • epithelial cell is well known in the art. Epithelial cells line cavities and surfaces of structures throughout the body and also form many glands. Epithelial tissues can be classified into simple epithelium (one cell thick) and stratified epithelium (several layers of cells). Epithelial cells are furthermore classified by their morphology into squamous, cuboidal, columnar and pseudostratified epithelial cells. For example, the human stomach and intestine is lined with epithelial cells. Further, epithelial cell lines include also breast carcinoma cells (such as, e.g., MCF7, MDA-MB-361 and T47D cells) or cells of the cell line HEK293T.
  • breast carcinoma cells such as, e.g., MCF7, MDA-MB-361 and T47D cells
  • adjuvant relates to a compound that enhances the efficiency of the lentiviral transduction.
  • adjuvants include e.g. a poloxamer having a molecular weight of 12.8 kDa to about 15 kDa and polybrene.
  • polystyrene resin is well known in the art and refers to a non-ionic triblock copolymer composed of a central hydrophobic chain of polyoxypropylene flanked by two hydrophilic chains of polyoxyethylene.
  • the lentiviral vector particles and the adjuvant can be added simultaneously, e.g. as a mixture, to the target cells or in sequential mode, as long as both compounds are simultaneously in contact with the target cell to allow transduction.
  • the present disclosure provides methods of providing gene therapy and lentivirus- based in vitro gene delivery, human naive T cell engineering, and genetic screens using murine T cells for T cell immunology and cancer immunology research.
  • the present disclosure provides methods of providing gene therapy for non-transducible cells.
  • Gene therapy can be performed by gene transfer, gene editing (e.g., CRISPR), exon skipping, RNA-interference, trans-splicing or any other genetic modification of any coding or regulatory sequences in the cell, including those included in the nucleus, mitochondria or as commensal DNA (viral sequences contained in cells).
  • the two main types of gene therapy are the following: a therapy aiming the replacement of a deficient/abnormal gene: this is replacement gene therapy; or a therapy aiming gene editing: in such a case, the purpose is to provide to a cell the necessary tools so that the gene of interest is expressed: this is gene editing therapy.
  • the gene of interest may be a correct version of a gene which is deficient or mutated in a patient, as is the case for example in a genetic disease.
  • the gene of interest will restore the expression of the deficient or mutated gene.
  • deficient or mutated genes in patients exhibiting a disease which, once corrected in immune cells, in particular in B cells, T cells, monocytes or dendritic cells, more particular in B cells, improve the patient's disease or symptoms.
  • the present pseudotyped lentiviral particles and chemically labeled cells in therapy for immune cell engineering, in particular T or B cell engineering, by transducing said immune cells. It might be possible to generate regulatory B cells by expressing immunosuppressive proteins in B cells, for instance IL- 10, or to induce the production of immunoregulatory proteins such as antibodies or fusion proteins.
  • the heterologous gene of interest is chosen from gRNA, nucleases, DNA templates and RNAi components, such as shRNA.
  • An immune cell is a cell involved in the immune system. It comprises notably B cells, T cells, NK cells, macrophages and dendritic cells.
  • a B cell (or B lymphocyte) is an immune cell responsible for the production of antibodies and involved in the humoral immune response.
  • a dendritic cell is an immune cell, which is accessory, i.e., it is an antigen-presenting cell. Its main function is to process the antigen material and present it on its cell surface to the T cells.
  • a T cell (or T lymphocyte) is an immune cell involved in cell-mediated immune response. It may be chosen from killer T cells, helper T cells and gamma delta T cells.
  • subject or “patient” as used herein refers to any individual to which the subject methods are performed.
  • the patient is human, although as will be appreciated by those skilled in the art, the patient may be an animal.
  • other animals including mammals such as rodents (including mice, rats, hamsters and guinea pigs), cats, dogs, rabbits, farm animals including cows, horses, goats, sheep, pigs, etc., and primates (including monkeys, chimpanzees, orangutans and gorillas) are included within the definition of patient.
  • Treatment and “treating” refer to administration or application of a therapeutic agent to a subject or performance of a procedure or modality on a subject for the purpose of obtaining a therapeutic benefit of a disease or health-related condition.
  • a treatment may include administration chemotherapy, immunotherapy, radiotherapy, performance of surgery, or any combination thereof.
  • therapeutic benefit refers to anything that promotes or enhances the well-being of the subject with respect to the medical treatment of this condition. This includes, but is not limited to, a reduction in the frequency or severity of the signs or symptoms of a disease.
  • treatment of cancer may involve, for example, a reduction in the invasiveness of a tumor, reduction in the growth rate of the cancer, or prevention of metastasis. Treatment of cancer may also refer to prolonging survival of a subject with cancer. III. Examples
  • a K562 cell line was developed with hLDLR knocked out via CRISPR-Cas9 to model various cell types with low hLDLR expression.
  • the CRISPR Cas9 cassette targeting the hLDLR gene locus was transduced into K562 cells via lentiviral vector.
  • the transduction efficiency of the hLDLR KO cells using BFP- expressing standard VS V-G pseudotyped lentivirus.
  • transduction by VSV-G pseudotyped lentivirus is only 7% (FIG. 3B), from a typical transduction efficiency of about 60% (FIG. 3A). This shows that transduction efficiency correlates with the presence of the hLDLR in K562 cells, confirming that a lack of hLDLR results in a lower transduction.
  • the hLDLR KO K562 cells were then chemically labelled with NHS-5’FAM at 1 LIM and transduced with a pseudotyped lentivirus expressing BFP.
  • NHS 5’FAM is a fluorescein molecule conjugated to N-hydroxysuccinimide at the 5 ’ carbon, allowing it to covalently form amide bonds with free primary amines.
  • This lentivirus contained both the standard VSV-G envelope and a chimeric protein scFv-truncVSVG, produced by transfection of HEK293T cells, using a 1 :1:0.25:0.25 plasmid mass ratio of sPAX:BFP:MD2G:scFv-truncVSVG.
  • scFv- truncVSVG is composed of the VSV-G intracellular domain and transmembrane domain fused to an N-terminus domain of an anti-fluorescein scFv, 2A9M derived from FITC-E2 (FIG. 2). This clone targets a region of FITC that is similar to 5 ’FAM, allowing it to be used.
  • Alternative anti-FITC scFvs such as 4m5.3, 4-4-20 (and variants) can be used here for generating the scFv- truncVSVG as well.
  • the transmembrane domain and intracellular domain could also be derived from proteins with minimal intracellular domain such as CD8-alpha, PDGFR, and MHC-class I.
  • the ratio of the plasmids for lentivirus preparation could be empirically determined.
  • the lentivirus vector can contain a fluorescent protein reporter (e.g., BFP, RFP), a chimeric antigen receptor (CAR), a therapeutic cytokine (e.g., IL2, IL12), a guide-RNA for CRISPR-based genome editing, or any other desired protein or non-protein-encoding gene.
  • Lentivirus can be used as crude culture supernatant, affinity purified, or concentrated using approaches such as ultracentrifugation.
  • Transduction was performed by adding equivalent volumes of cells at le6 cells/mL and lentiviral supernatant collected from HEK293T cells at 60 hrs post- transfection. Polybrene (10 mg/ml) was added at lOOOx dilution and the viral-cell mix was centrifuged at 2000g for 1.5 hrs at 35°C. Transduction of labelled hLDLR KO K562 cells with scFv-truncVSVG pseudotyped viruses resulted in a significant increase from 4% to 32% transduction efficiency (FIGS. 3C- 3D). This showed that the strategy of chemical labelling and transduction with pseudotyped lentivirus resulted in increased transduction efficiency in cells with low expression of hLDLR.
  • the raw viral supernatant collected from HEK293T cells 60hrs post-transfection was centrifuged at 15,600 rpm for 20 hrs at 4°C and resulting in a 20-fold concentrated viral supernatant and raising virus titer 20- fold.
  • the lentiviral transduction efficiency increased to 72% (FIG. 4, bottom left), equivalent to transduction of wt K562 cells with standard lentivirus. (FIG. 3A).
  • transduction of the unlabeled WT K562 cells or hLDLR KO with concentrated virus was slightly increased (FIG. 4, upper panels), likely due to the non-specific and inefficient cell-intrinsic micropinocytosis.
  • dilutions of the concentrated viral supernatant resulted in corresponding drops in transduction efficiency (FIG. 4, bottom panels), proving that raised transduction was due to an increase in viral particle concentration.
  • a strategy was developed that facilitates transduction of cells with low hLDLR expressing cells to an equivalent level of efficiency as optimal transduction efficiencies in hLDLR expressing cells.
  • scFv-truncVSVG pseudotyped viruses could deliver a transgene efficiently to mammalian cells conjugated with FITC molecules via a chemical approach, including NHS-chemistry (NHS-FITC/5’FAM), lipid insertion (DSPE-PEG-FITC, l,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [poly (ethylene glycol)2000-N'-carboxyfluorescein] (ammonium salt)), and maleimide chemistry (Mal-FITC/5’FAM) (Fig. 6).
  • NHS-chemistry NHS-chemistry
  • DSPE-PEG-FITC lipid insertion
  • Mal-FITC/5’FAM maleimide chemistry
  • the inventors carried out systemic optimization of the chemical approach for labeling mammalian cells with FITC.
  • For the lipid insertion approach they assessed the impact of the PEG linker length and found that DSPE-PEG-FITC with a PEG5k linker performs the best in assisting virus transduction (Fig. 9).
  • For the maleimide-chemistry approach they tested the impact of different concentrations of Mal-FITC and found that cells were most strongly labeled with 5 pM Mal-FITC (Fig. 10). Given that all three labeling approaches (Fig. 5) are orthogonal, the inventors hypothesized that cell labeling with a combination of these labeling approaches could maximize the surface labeling with FITC and therefore likely enable the optimal virus transduction.
  • the inventors then tested the virus binding to WT and hLDLR-KO K562 cells and confirmed stronger virus binding to WT K562 cells, indicating this binding is strongly dependent on hLDLR (Fig. 14, left panel). They went on and tested the virus binding and hLDLR expression on a panel of mammalian cell lines, including SUP-B15, C1498, 58-/- hybridoma, Jurkat and NALM6. They found that virus transduction has a stronger correlation with virus binding than hLDLR expression (Fig. 14 mid, right panel), indicating other membrane proteins (e.g., LDLR family members) could assist virus binding and cell transduction. Chemically labeling improved virus transduction of all mammalian cell lines (Fig.
  • naive human T cells with a scFv-truncVSVG pseudotyped virus carrying a CD 19 CAR followed by surface labeling using FITC-conjugated antibodies (anti-CD5, anti- CD45).
  • CD 19 CAR expression on naive T cells was measured by flow cytometry 7 days posttransduction, and they found that >30% naive T cells express the CD19 CAR.
  • most transduced T cells maintained their naive phenotype (CD45RA+, CCR7+) (Fig. 16).
  • FITC-anti-CD19 included as control
  • FITC-anti-CD5 directed virus transduction performed the best in the presence of polybrene (Fig. 17). And all approaches could efficiently transduce (30-60%) naive T cells (CD45RA+, CCR7+) (Fig. 18).
  • compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this disclosure have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the disclosure. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the disclosure as defined by the appended claims.
  • Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA. 1993; 90(17): 8033-8037.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente divulgation concerne des méthodes d'amélioration de l'efficacité de transduction de cellules non transductibles, telles que des cellules à faible hLDLR. Les cellules peuvent être marquées avec du 5'FAM et transduites avec un lentivirus pseudotypé VSV-G tronqué par scFv qui comprend un scFv anti-fluorescéine. L'invention concerne en outre des méthodes de thérapie génique, d'ingénierie cellulaire, de criblage génétique et de modèles de maladie à l'aide des cellules marquées à la fluorescéine transduites avec le lentivirus pseudotypé VSV-G tronqué par scFv.
PCT/US2024/035972 2023-06-30 2024-06-28 Ingénierie de surface cellulaire d'une distribution de gène thérapeutique personnalisée Ceased WO2025006848A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24832987.2A EP4735583A1 (fr) 2023-06-30 2024-06-28 Ingénierie de surface cellulaire d'une distribution de gène thérapeutique personnalisée

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363511468P 2023-06-30 2023-06-30
US63/511,468 2023-06-30

Publications (1)

Publication Number Publication Date
WO2025006848A1 true WO2025006848A1 (fr) 2025-01-02

Family

ID=93939877

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/035972 Ceased WO2025006848A1 (fr) 2023-06-30 2024-06-28 Ingénierie de surface cellulaire d'une distribution de gène thérapeutique personnalisée

Country Status (2)

Country Link
EP (1) EP4735583A1 (fr)
WO (1) WO2025006848A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180104354A1 (en) * 2013-10-15 2018-04-19 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
US20180171028A1 (en) * 2015-05-13 2018-06-21 Zumutor Biologics, Inc. Afucosylated protein, cell expressing said protein and associated methods
US20190271006A1 (en) * 2016-11-10 2019-09-05 Kaneka Corporation Method for producing transgenic cell
US20210301307A1 (en) * 2018-08-30 2021-09-30 Miltenyi Biotec B.V. & Co. KG Ldlr negative packaging cell line for the production of vsv-g pseudotyped retroviral vector particles or virus particles thereof
US20220395478A1 (en) * 2017-05-19 2022-12-15 Memorial Sloan Kettering Cancer Center Methods for modifying endoplasmic reticulum processing of protein

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180104354A1 (en) * 2013-10-15 2018-04-19 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
US20180171028A1 (en) * 2015-05-13 2018-06-21 Zumutor Biologics, Inc. Afucosylated protein, cell expressing said protein and associated methods
US20190271006A1 (en) * 2016-11-10 2019-09-05 Kaneka Corporation Method for producing transgenic cell
US20220395478A1 (en) * 2017-05-19 2022-12-15 Memorial Sloan Kettering Cancer Center Methods for modifying endoplasmic reticulum processing of protein
US20210301307A1 (en) * 2018-08-30 2021-09-30 Miltenyi Biotec B.V. & Co. KG Ldlr negative packaging cell line for the production of vsv-g pseudotyped retroviral vector particles or virus particles thereof

Also Published As

Publication number Publication date
EP4735583A1 (fr) 2026-05-06

Similar Documents

Publication Publication Date Title
CN101720332B (zh) 生产促卵泡激素的细胞克隆
CN107557388B (zh) 一种用于car-t制备的慢病毒载体及其构建方法和应用
CN108949693A (zh) 一种对t细胞免疫检测点通路进行基因敲除的方法及应用
CN109706185A (zh) 基于碱基编辑系统突变起始密码子实现基因敲除的方法及应用
AU2024219754A1 (en) T cell receptors which recognize mutated EGFR
US20040071673A1 (en) Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
US8148143B2 (en) Method and composition for genetically modifying non-human cells and animals
CA2404100A1 (fr) Therapie anti-cancereuse : peptides therapeutiques avec motif se liant specifiquement a des histones h3 et h4 non acetyles
CN106701806B (zh) 评估中药和/或天然药物效能的系列转录因子报告基因系统及其应用
CN109929847B (zh) 一种pex26基因、蛋白及其应用
US20040209800A1 (en) Use of mx gtpases in the prognosis and treatment of cancer
US6379927B1 (en) Retinoblastoma fusion proteins
CN115044585B (zh) 一种真核细胞启动子cf1及其在细胞基因表达中的应用
EP4735583A1 (fr) Ingénierie de surface cellulaire d'une distribution de gène thérapeutique personnalisée
US20030182668A1 (en) Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
KR20090119283A (ko) 녹색형광단백질을 이용한 단백질 과발현 시스템의 향상
KR101876486B1 (ko) Myh4 유전자를 포함하는 재조합 벡터 및 이의 이용
KR102713784B1 (ko) Tlr2 과발현 죽상동맥경화 동물 모델 및 이의 제조방법
KR101446388B1 (ko) Ｂ형 간염 바이러스의 ｐｒｅＳ1 Ｗ4Ｐ 변이 단백질을 발현하는 형질전환 동물 및 이의 용도
GB2425534A (en) Epsilon poly-L-lysine-nucleic acid complex
KR20170017115A (ko) 단백질분해효소억제제, 역전사효소억제제 및 통합효소억제제 내성도 동시 예측을 위한 유전형 및 표현형검사법
CN116672442B (zh) 藁本内酯与her2-car-t细胞联合制备治疗骨肉瘤的药物
CN112626029B (zh) 一种转基因修饰的Daudi细胞及其制备方法、应用
US6074850A (en) Retinoblastoma fusion polypeptides
CN114317536B (zh) 基于CRISPR/Cas9构建uPA转基因小鼠的制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24832987

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2024832987

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024832987

Country of ref document: EP

Effective date: 20260130

ENP Entry into the national phase

Ref document number: 2024832987

Country of ref document: EP

Effective date: 20260130

WWP Wipo information: published in national office

Ref document number: 2024832987

Country of ref document: EP